FIB Funding Opportunity Announcements (FOAs)

Type of FOA:

- Any -RFAPA/PAR/PAS

Go

Announcement Number Sort descending	Submissions Date(s)	Expiration Date	Activity Code(s)	Title
PA-16-087	Multiple dates, see announcement.	May 8, 2019	R21	Oocyte Mitochondrial Function in Relation to Fertility, Aging, and Mitochondrial Diseases (R21)
PA-16-088	Multiple dates, see announcement.	May 8, 2019	R01	Oocyte Mitochondrial Function in Relation to Fertility, Aging, and Mitochondrial Diseases (R01)
PA-16-444	Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.	January 8, 2020	R21	Trophoblast Differentiation and Function (R21)
PA-16-445	Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.	January 8, 2020	R01	Trophoblast Differentiation and Function (R01)
PA-17-091	Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. The first standard application due date for this FOA is June 5, 2017. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.	May 8, 2020	R01	Fertility Status as a Marker for Overall Health (R01)
PA-17-092	Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. The first standard application due date for this FOA is June 16, 2017. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.	May 8, 2020	R21	Fertility Status as a Marker for Overall Health (R21)
PA-18-838	Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. The first standard application due date for this FOA is October 5, 2018. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.	September 8, 2021	R01	Role of Gut Microbiome in Regulating Reproduction and Its Impact on Fertility Status in Women Living with and Without HIV (R01 - Clinical Trial Optional)
PA-18-839	Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. The first standard application due date for this FOA is October 16, 2018. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.	September 8, 2021	R21	Role of Gut Microbiome in Regulating Reproduction and Its Impact on Fertility Status in Women Living with and Without HIV (R21 Clinical Trial Optional)
PAR-16-114	June 5, 2016; June 5, 2017; June 5, 2018, by 5:00 PM local time of applicant organization.	June 6, 2018	R01	Spermatogenic Stem Cell Culture Systems to Preserve and Restore Reproductive Capacity in Males (R01)
PAR-16-366	September 27, 2016; September 27, 2017; September 27, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.	September 28, 2018	R01	Dual Purpose with Dual Benefit: Research in Biomedicine and Agriculture Using Agriculturally Important Domestic Animal Species (R01)
PAR-18-830	November 7, 2018, June 3, 2019, March 3, 2020, November 7, 2020, June 3, 2021, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.	June 4, 2021	R01	The Role of Epitranscriptomics in Development and Disease (R01 - Clinical Trial Not Allowed)
PAR-18-831	November 7, 2018, June 3, 2019, March 3, 2020, November 7, 2020, June 3, 2021, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.	June 4, 2021	R21	The Role of Epitranscriptomics in Development and Disease (R21 - Clinical Trial Not Allowed)
RFA-HD-18-007	October 30, 2017, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.	October 31, 2017	K12	Reproductive Scientist Development Program (RSDP) (K12)
RFA-HD-18-008	November 27, 2017, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. No late applications will be accepted for this Funding Opportunity Announcement (FOA) .	November 28, 2017	P50	National Centers for Translational Research in Reproduction and Infertility (P50)
RFA-HD-19-017	June 29, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.	June 30, 2018	P50	National Centers for Translational Research in Reproduction and Infertility [NCTRI] (P50 - Clinical Trial Optional)

BACK TO TOP